Kazia Therapeutics Limited Stock News

Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) valuation has increased to A$346 million or A$2.68 per share from A$301 million or A$2.32 per share following the company's in-licensing of E

Kazia Therapeutics Ltd (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) has entered into a worldwide exclusive licensing agreement as well as a master services agreement with Evotec SE (FRA:EVT) – a leading Europe

The stock price of Kazia Therapeutics Ltd (NASDAQ: KZIA) increased by 3% pre-market. This is why it happened.

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) is in a trading halt pending an announcement in regard to a potential in-licensing transaction. In its application to the ASX for the halt, K

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has secured an increased price target from A$2.25 to A$2.60 a share by Corporate Connect analyst Marc Sinatra on the back of two recent licens

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) will share new data from its ongoing phase II study of paxalisib in glioblastoma in a poster presentation at the prestigious American Associati

LONDON, UK / ACCESSWIRE / March 30, 2021 / Kazia (NASDAQ:KZIA) has announced it has signed an agreement for the Greater China rights to paxalisib with Simcere Pharmaceuticals. The deal includes an US$

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (HKSE:2096) to develop and commercialise Kazia's investigational n

The stock price of Kazia Therapeutics Ltd (NASDAQ: KZIA) increased by over 20% pre-market. This is why it happened.

Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd to develop and commercialize Kazia's investigational new drug, paxalisib, in Gr

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has been granted a trading halt by the ASX pending the release of an announcement regarding a regional licensing transaction. The halt will be

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) chief executive officer and MD James Garner has highlighted the company's progress over the course of the year to date in its March newslett

Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovari

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) made substantial progress and achieved key milestones in the half-year ending December 31, 2020, ending the period with a cash balance of A$1

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted